Supramolecular Chiral Binding Affinity‐Achieved Efficient Synergistic Cancer Therapy
Advanced Science · 2024
DOI: 10.1002/advs.202308493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Jinfeng Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, Jiangsu, 225002, P. R. China. Hauptthemen laut MEDLINE: Doxorubicin, Antineoplastic Agents, Indocyanine Green, Nanoparticles. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.
Abstract (Originalsprache)
Supramolecular chirality‐mediated selective interaction among native assemblies is essential for precise disease diagnosis and treatment. Herein, to fully understand the supramolecular chiral binding affinity‐achieved therapeutic efficiency, supramolecular chiral nanoparticles (WP5⊃D/L‐Arg+DOX+ICG) with the chirality transfer from chiral arginine (D/L‐Arg) to water‐soluble pillar[5]arene (WP5) are developed through non‐covalent interactions, in which an anticancer drug (DOX, doxorubicin hydrochloride) and a photothermal agent (ICG, indocyanine green) are successfully loaded. Interestingly, the WP5⊃D‐Arg nanoparticles show 107 folds stronger binding capability toward phospholipid‐composed liposomes compared with WP5⊃L‐Arg. The enantioselective interaction further triggers the supramolecular chirality‐specific drug accumulation in cancer cells. As a consequence, WP5⊃D‐Arg+DOX+ICG exhibits extremely enhanced chemo‐photothermal synergistic therapeutic efficacy (tumor inhibition rate of 99.4%) than that of WP5⊃L‐Arg+DOX+ICG (tumor inhibition rate of 56.4%) under the same condition. This work reveals the breakthrough that supramolecular chiral assemblies can induce surprisingly large difference in cancer therapy, providing strong support for the significance of supramolecular chirality in bio‐application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, Jiangsu, 225002, P. R. China.
- School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225002, P. R. China.
- College of Chemistry, State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Yu Liu
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
Zitieren
APA
Zhou, J., Gu, J., Sun, X., Ye, Q., Wu, X., Xi, J., Han, J., & Liu, Y. (2024). Supramolecular Chiral Binding Affinity‐Achieved Efficient Synergistic Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202308493
Vancouver
Zhou J, Gu J, Sun X, Ye Q, Wu X, Xi J, et al. Supramolecular Chiral Binding Affinity‐Achieved Efficient Synergistic Cancer Therapy. Advanced Science. 2024. doi:10.1002/advs.202308493
BibTeX
@article{Zhou2024,
author = {Zhou, Jinfeng and Gu, Jiake and Sun, Xiaohuan and Ye, Qianyun and Wu, Xuan and Xi, Juqun and Han, Jie and Liu, Yu},
title = {Supramolecular Chiral Binding Affinity‐Achieved Efficient Synergistic Cancer Therapy},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202308493}
}
EUVIMED